

To the Press:

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

8 July 2013

Exiqon Awarded Global microRNA Research Tools Company of the Year by Frost & Sullivan

Exiqon A/S (NASDAQ OMX: "EXQ"), a leading supplier of high-value products for gene expression analysis, today announced that Frost & Sullivan has recognized Exiqon as the recipient of the 2013 Company of the Year Award in Global microRNA Research Tools in light of the excellence that Exiqon has exhibited in the microRNA research space. This award follows Frost & Sullivan's most recent analysis of the global microRNA research tools and services market.

Exiqon was one of the first companies to commercially serve the microRNA market and scientists around the world have published thousands of peer-reviewed scientific papers based on Exiqon's microRNA research products since the first product introductions in 2005.

Most recently, Exiqon has developed a database search tool, miRSearch, which allows customers to do simple and intuitive searches across a dozen relevant databases and easily navigate the overwhelming amount of microRNA information when designing experiments. The search tool is accessible at www.exiqon.com/mirsearch. This recent extension complements Exiqon's leading miRCURY LNA™ products for microRNA research that include validated microRNA products for sample extraction, gene expression and functional analysis, as well as advanced software for data analysis.

Exiqon has been cited as a preferred one-stop shop provider of complete workflow solutions pertaining to microRNA research. Provision of microRNA profiling and screening services along with products has not only simplified purchasing, but has also attracted new customers for Exiqon.

"Over the past eight years, the microRNA research space has evolved from an exotic research field to an emerging market which includes validated biomarkers and clinical applications," says Exiqon CEO Lars Kongsbak. "According to Frost & Sullivan analysis, Exiqon holds an average market share of 24 percent, thereby continuing to be instrumental in helping scientists across industry and academia understand and apply the biology of microRNAs".

Frost & Sullivan does not accept nominations or submissions for Frost & Sullivan Awards. The selection of this Award comes through in-depth interviews and primary market analysis conducted by Frost & Sullivan's industry analyst team.



About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer-treating physicians working towards personalizing medicine. Exiqon operates in two business areas. Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells and body fluids. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to target new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

Additional information from Exiqon

Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

The "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

- The Integrated Value Proposition provides support to clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes a 360 degree research, comprehensive industry coverage, career best practices as well as Frost & Sullivan's global footprint of more than 40 offices.

For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Frost & Sullivan prepares its clients for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies.

Additional information from Frost & Sullivan

Mireya Espinoza
Frost & Sullivan
Corporate Communications – North America
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com

